(NASDAQ:IMMX) IMMIX BIOPHARM INC. share are rallying this morning in pre-market up to $2.66 a share.  Shares are up more than 43% on more than 21,000 trades one hour before the open.

ImmixBio IMX-110 Demonstrated Improved Survival Over U.S. Food and Drug Administration Approved Drug Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) in Connective Tissue Cancer Soft Tissue Sarcoma Mice Study

  • One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug)
  • In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs
  • IMX-110 is in clinical development for STS, a $3 billion market expected to grow to $6.5 billion by 2030

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/38fdaa24-38ff-482c-8b72-63baa730a3a2


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.